Programs Generally. The Parties will jointly conduct each Program. It is intended that Arcturus will be responsible for the lipid chemistry and LMD formulation using the Arcturus LMD Technology, and for characterization work, CureVac will be responsible for mRNA Construct development, and Arcturus and CureVac will each undertake preclinical studies as allocated in each Work Plan.
Appears in 2 contracts
Sources: Development and Option Agreement (CureVac B.V.), Development and Option Agreement (Arcturus Therapeutics Ltd.)